(firstQuint)Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis.

 The trial is an open label extension study.

 Eligible patients from the RPC01-3101 trial diagnosed with moderate to severe ulcerative colitis will be enrolled to receive study medication for up to 5 years or until marketed approval.

.

 Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis@highlight

The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients diagnosed with moderate to severe ulcerative colitis.

